CHICAGO (Reuters) - Two studies in monkeys published on Wednesday offer some of the first scientific evidence that surviving COVID-19 may result in immunity from reinfection, a positive sign that vaccines under development may succeed, U.S. researchers said on Wednesday.
Although scientists have assumed that antibodies produced in response to the new coronavirus virus are protective, there has been scant scientifically rigorous evidence to back that up.
In one of the new studies, researchers infected nine monkeys with COVID-19, the illness caused by the novel coronavirus. After they recovered, the team exposed them to the virus again and the animals did not get sick.
The findings suggest that they “do develop natural immunity that protects against re-exposure,” said Dr. Dan Barouch, a researcher at the Center for Virology and Vaccine Research at Harvard’s Beth Israel Deaconness Medical Center in Boston, whose studies were published in the journal Science.
“It’s very good news,” Barouch said.
Several research teams have released papers - many of them not reviewed by other scientists - suggesting that a vaccine against the virus would be effective in animals.
In the second study, Barouch and colleagues tested 25 monkeys with six prototype vaccines to see if antibodies produced in response were protective.
They then exposed these monkeys and 10 control animals to SARS-CoV-2, the official name of the novel coronavirus.
All of the control animals showed high degrees of virus in their noses and lungs, but in the vaccinated animals, “we saw a substantial degree of protection,” Barouch said. Eight of the vaccinated animals were completely protected.
These studies, which have been peer reviewed, do not prove that humans develop immunity or how long it might last, but they are reassuring.
“These data will be seen as a welcome scientific advance,” Barouch said.
Reporting by Julie Steenhuysen; Editing by Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.